Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $3.3B | $566M | $-78M | $196M | -4.5% | 6.2% | -53.7% |
| 2024 | $3.1B | $501M | $-168M | $210M | -9.4% | 13.5% | 1312.6% |
| 2023 | $2.7B | $446M | $-12M | $205M | -0.6% | 8.0% | -78.2% |
| 2022 | $2.5B | $460M | $-55M | $78M | -2.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 3,308.70 |
| Operating Revenue | 3,308.70 |
| Cost Of Revenue | 2,543.70 |
| Gross Profit | 765 |
| Operating Expense | 294.20 |
| Selling General And Administration | 118.20 |
| Total Expenses | 2,837.90 |
| Operating Income | 470.80 |
| Total Operating Income As Reported | 389.50 |
| EBITDA | 565.50 |
| Normalized EBITDA | 678.40 |
| EBIT | 389.50 |
| Interest Expense | 272.60 |
| Net Interest Income | -272.60 |
| Other Non Operating Income Expenses | 8.70 |
| Other Income Expense | -81.30 |
| Interest Expense Non Operating | 272.60 |
| Net Non Operating Interest Income Expense | -272.60 |
| Pretax Income | 116.90 |
| Tax Provision | 18 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -17.39 |
| Net Income Continuous Operations | 98.90 |
| Net Income From Continuing And Discontinued Operation | -77.90 |
| Net Income From Continuing Operation Net Minority Interest | -77.90 |
| Net Income | -77.90 |
| Net Income Common Stockholders | -77.90 |
| Net Income Including Noncontrolling Interests | 98.90 |
| Normalized Income | 17.61 |
| Diluted NI Availto Com Stockholders | -77.90 |
| Basic Average Shares | 127.21 |
| Diluted Average Shares | 127.21 |
| Reconciled Depreciation | 176 |
| Reconciled Cost Of Revenue | 2,543.70 |
| Total Unusual Items | -112.90 |
| Total Unusual Items Excluding Goodwill | -112.90 |
| Minority Interests | -176.80 |
| Special Income Charges | -112.90 |
| Gain On Sale Of Business | -30.40 |
| Other Special Charges | 8.60 |
| Write Off | - |
| Impairment Of Capital Assets | - |
| Restructuring And Mergern Acquisition | 73.90 |
| Depreciation Amortization Depletion Income Statement | 176 |
| Depreciation And Amortization In Income Statement | 176 |
| General And Administrative Expense | 118.20 |
| Other Gand A | 118.20 |
| Gain On Sale Of Ppe | - |
| Rent Expense Supplemental | 87.90 |
| Other Operating Expenses | - |
| Otherunder Preferred Stock Dividend | - |
| Earnings From Equity Interest | 22.90 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Surgery Partners, Inc.this co. | SGRY | $1.8B | -22.97 | 1.04 | -4.5% | 9.86 |
| Maravai LifeSciences Holdings, Inc. | MRVI | $1.8B | -14.08 | 8.67 | -61.6% | -13.48 |
| Pediatrix Medical Group, Inc. | MD | $1.8B | 11.11 | 2.12 | 19.1% | 7.64 |
| Viridian Therapeutics, Inc. | VRDN | $1.8B | -5.34 | 3.10 | -58.1% | -4.95 |
| Vericel Corporation | VCEL |
| - |
| - |
| - |
| - |
| - |
| - |
| $1.8B |
| 110.33 |
| 5.14 |
| 4.7% |
| 60.29 |
| ANI Pharmaceuticals, Inc. | ANIP | $1.8B | 22.99 | 3.33 | 14.5% | 10.29 |
| Nuvation Bio Inc. | NUVB | $1.8B | -8.80 | 5.89 | -66.9% | -8.95 |
| Rapport Therapeutics, Inc. | RAPP | $1.8B | - | -178.20 | -23.0% | - |
| SELLAS Life Sciences Group, Inc. | SLS | $1.8B | -66.17 | 25.08 | -37.9% | -60.37 |
| Peer Median | - | -5.34 | 4.23 | -30.5% | -4.95 | |